Literature DB >> 28726804

Diagnostic cytogenetic testing following positive noninvasive prenatal screening results: a clinical laboratory practice resource of the American College of Medical Genetics and Genomics (ACMG).

Athena M Cherry1, Yassmine M Akkari2, Kimberly M Barr3, Hutton M Kearney4, Nancy C Rose5, Sarah T South6, James H Tepperberg7, Jeanne M Meck8.   

Abstract

Disclaimer: ACMG Clinical Laboratory Practice Resources are developed primarily as an educational tool for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these practice resources is voluntary and does not necessarily assure a successful medical outcome. This Clinical Laboratory Practice Resource should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with this Clinical Laboratory Practice Resource. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.Noninvasive prenatal screening (NIPS) using cell-free DNA has been rapidly adopted into prenatal care. Since NIPS is a screening test, diagnostic testing is recommended to confirm all cases of screen-positive NIPS results. For cytogenetics laboratories performing confirmatory testing on prenatal diagnostic samples, a standardized testing algorithm is needed to ensure that the appropriate testing takes place. This algorithm includes diagnostic testing by either chorionic villi sampling or amniocentesis samples and encompasses chromosome analysis, fluorescence in situ hybridization, and chromosomal microarray.

Entities:  

Mesh:

Year:  2017        PMID: 28726804     DOI: 10.1038/gim.2017.91

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  Accurate description of DNA-based noninvasive prenatal screening.

Authors:  Sau W Cheung; Ankita Patel; Tak Y Leung
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

Review 2.  Noninvasive detection of fetal trisomy 21: systematic review and report of quality and outcomes of diagnostic accuracy studies performed between 1997 and 2012.

Authors:  E Mersy; L J M Smits; L A A P van Winden; C E M de Die-Smulders; A D C Paulussen; M V E Macville; A B C Coumans; S G M Frints
Journal:  Hum Reprod Update       Date:  2013-02-08       Impact factor: 15.610

3.  Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use.

Authors:  E B Hook
Journal:  Am J Hum Genet       Date:  1977-01       Impact factor: 11.025

Review 4.  Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy.

Authors: 
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

5.  X chromosome aneuploidy in lymphocyte cultures from women with recurrent spontaneous abortions.

Authors:  D E Horsman; F J Dill; B C McGillivray; D K Kalousek
Journal:  Am J Med Genet       Date:  1987-12

6.  Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing.

Authors:  Yanlin Wang; Yan Chen; Feng Tian; Jianguang Zhang; Zhuo Song; Yi Wu; Xu Han; Wenjing Hu; Duan Ma; David Cram; Weiwei Cheng
Journal:  Clin Chem       Date:  2013-11-05       Impact factor: 8.327

7.  Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors.

Authors:  Ghalia Ashoor; Leona Poon; Argyro Syngelaki; Beatrice Mosimann; Kypros H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2012-05-04       Impact factor: 2.587

8.  Discordant noninvasive prenatal testing and cytogenetic results: a study of 109 consecutive cases.

Authors:  Jia-Chi Wang; Trilochan Sahoo; Steven Schonberg; Kimberly A Kopita; Leslie Ross; Kyla Patek; Charles M Strom
Journal:  Genet Med       Date:  2014-08-07       Impact factor: 8.822

9.  ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013.

Authors:  Sarah T South; Charles Lee; Allen N Lamb; Anne W Higgins; Hutton M Kearney
Journal:  Genet Med       Date:  2013-09-26       Impact factor: 8.822

10.  DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study.

Authors:  Glenn E Palomaki; Cosmin Deciu; Edward M Kloza; Geralyn M Lambert-Messerlian; James E Haddow; Louis M Neveux; Mathias Ehrich; Dirk van den Boom; Allan T Bombard; Wayne W Grody; Stanley F Nelson; Jacob A Canick
Journal:  Genet Med       Date:  2012-02-02       Impact factor: 8.822

View more
  7 in total

1.  50 Years Ago in TheJournalofPediatrics: From Chromosomes to Clinical Care: Klinefelter Syndrome.

Authors:  Louise C Pyle; Jacqueline M M Leonard; Ian D Krantz
Journal:  J Pediatr       Date:  2022-04       Impact factor: 4.406

2.  Positive predictive value estimates for noninvasive prenatal testing from data of a prenatal diagnosis laboratory and literature review.

Authors:  Siping Liu; Fang Yang; Qingxian Chang; Bei Jia; Yushuang Xu; Ruifeng Wu; Liyan Li; Weishan Chen; Ailan Yin; Fodi Huang; Suxin Feng; Fenxia Li
Journal:  Mol Cytogenet       Date:  2022-07-06       Impact factor: 1.904

3.  Performance of cell-free DNA sequencing-based non-invasive prenatal testing: experience on 36,456 singleton and multiple pregnancies.

Authors:  Marco La Verde; Luigia De Falco; Annalaura Torella; Giovanni Savarese; Pasquale Savarese; Raffaella Ruggiero; Anna Conte; Vera Fico; Marco Torella; Antonio Fico
Journal:  BMC Med Genomics       Date:  2021-03-30       Impact factor: 3.063

4.  Prenatal Diagnostic Testing Following High-Risk Result from Serological Screening: Which Shall We Select?

Authors:  Jing Wang; Xin-Xin Tang; Qin Zhou; Shuting Yang; Ye Shi; Bin Yu; Bin Zhang; Lei-Lei Wang
Journal:  Int J Womens Health       Date:  2021-09-22

5.  Clinical Selection of Prenatal Diagnostic Techniques Following Positive Noninvasive Prenatal Screening Results in Southwest China.

Authors:  Xiaosha Jing; Hongqian Liu; Qian Zhu; Sha Liu; Jianlong Liu; Ting Bai; Cechuan Deng; Tianyu Xia; Yunyun Liu; Jing Cheng; Xiang Wei; Lingling Xing; Yuan Luo; Quanfang Zhou; Lin Chen; Lingping Li; Jiamin Wang
Journal:  Front Genet       Date:  2022-01-28       Impact factor: 4.599

6.  Clinical experience of noninvasive prenatal testing for rare chromosome abnormalities in singleton pregnancies.

Authors:  Ting Hu; Jiamin Wang; Qian Zhu; Zhu Zhang; Rui Hu; Like Xiao; Yunyuan Yang; Na Liao; Sha Liu; He Wang; Xiaoyu Niu; Shanling Liu
Journal:  Front Genet       Date:  2022-09-26       Impact factor: 4.772

7.  The Necessity of Prenatal Diagnosis by CMA for the Women with NIPS-Positive Results.

Authors:  Jun Xu; Ying Xue; Jing Wang; Qin Zhou; Bin Zhang; Bin Yu; Ting Wang
Journal:  Int J Genomics       Date:  2020-08-29       Impact factor: 2.326

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.